Synapse - Robert Motzer

Search Within

Robert Motzer

Results (1247)

Expression of T-cell exhaustion molecules and human endogenous retroviruses as predictive biomarkers for response to nivolumab in metastatic clear cell renal cell carcinoma

Journal Article

Ficial, M.; Jegede, O. A.; Sant'Angelo, M.; Hou, Y.; Flaifel, A.; Pignon, J. C.; Braun, D. A.; Wind-Rotolo, M.; Sticco-Ivins, M. A.; Catalano, P. J.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT trial

Journal Article

Motzer, R. J.; Russo, P.; Haas, N.; Doehn, C.; Donskov, F.; Gross-Goupil, M.; Varlamov, S.; Kopyltsov, E.; Lee, J. L.; Lim, H. Y.; more...
European Urology (2021)

Fulltext@MSK | Save

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting

Journal Article

Patel, A.; Ravaud, A.; Motzer, R. J.; Pantuck, A. J.; Staehler, M.; Escudier, B.; Martini, J. F.; Lechuga, M.; Lin, X.; George, D. J.
Future Oncology (2021)

Fulltext@MSK | Save

Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal Article

Tannir, N. M.; Signoretti, S.; Choueiri, T. K.; McDermott, D. F.; Motzer, R. J.; Flaifel, A.; Pignon, J. C.; Ficial, M.; Frontera, O. A.; George, S.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

Journal Article

Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Ikezawa, H.; Sachdev, P.; Dutcus, C. E.; more...
British Journal of Cancer (2021)

Fulltext@MSK | Save

Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Journal Article

Tannir, N. M.; Powles, T.; Escudier, B.; Donskov, F.; Grunwald, V.; Sternberg, C. N.; Schmidinger, M.; Schoffski, P.; Szczylik, C.; Peltolta, K.; more...
Kidney Cancer (2020)

Fulltext@MSK | Save

Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials

Meeting Abstract

McQuade, J. L.; Hammers, H. J.; Furberg, H.; Engert, A.; Andre, T.; Blumenschein, G.; Tannir, N. M.; Baron, A. D.; Larkin, J.; El-Khoueiry, A. B.; more...
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Kotecha, R.; Lee, C. H.; Knezevic, A.; Shah, N. J.; Carlo, M. I.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk

Meeting Abstract

Choueiri, T. K.; Albiges, L.; Powles, T.; Scheffold, C.; Wang, F.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save

A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914)

Meeting Abstract

Bex, A.; Russo, P.; Tomita, Y.; Grunwald, V.; Ramirez, L. M.; McHenry, B. M.; Motzer, R. J.
Journal of Clinical Oncology (2020)

Fulltext@MSK | Save